[Not Available].

Over the past decade, treatment with immune checkpoint inhibitors (ICI) has been implemented in cancer treatment. It has led to a significant improvement in the prognosis for many types of cancer. ICIs work by inducing the body's immune response against cancer cells. Unfortunately, they can also cause immune-related adverse events in most organ systems, with skin-related adverse events being among the most common. This review provides an overview of existing evidence and clinical experience regarding managing dermatological adverse events associated with ICIs.